Barinthus Biotherapeutics plc Files Q1 2025 10-Q
Ticker: BRNS · Form: 10-Q · Filed: May 7, 2025 · CIK: 1828185
| Field | Detail |
|---|---|
| Company | Barinthus Biotherapeutics PLC. (BRNS) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
Barinthus Biotherapeutics plc filed its Q1 2025 10-Q. Financials and corporate info updated.
AI Summary
Barinthus Biotherapeutics plc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Vaccitech plc, is focused on pharmaceutical preparations. Key financial data and corporate structure details are provided in this filing.
Why It Matters
This filing provides investors with an update on Barinthus Biotherapeutics' financial health and operational status for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Barinthus Biotherapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Barinthus Biotherapeutics plc. (company) — Filer of the 10-Q
- Vaccitech plc (company) — Former name of Barinthus Biotherapeutics plc.
- 20250331 (date) — End of the reporting period
- 20250507 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period is for the quarter ended March 31, 2025.
What was Barinthus Biotherapeutics plc formerly known as?
Barinthus Biotherapeutics plc was formerly known as Vaccitech plc.
What is the Standard Industrial Classification code for Barinthus Biotherapeutics plc?
The SIC code is 2834, Pharmaceutical Preparations.
When was the company's name changed from Vaccitech plc?
The date of the name change from Vaccitech plc was April 7, 2021.
What is the business address of Barinthus Biotherapeutics plc?
The business address is Unit 6-10, Zeus Building, Rutherford Avenue, Harwell, Didcot, OX11 0DF.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Barinthus Biotherapeutics plc. (BRNS).